Today: 9 July 2026
Browse Category

Earnings Reports 7 November 2025 - 9 November 2025

P&G Earnings Smash Estimates – Beauty Boom and Razors Fly Off Shelves in Q1

PG Stock Today: What to Know Before the Bell on November 10, 2025 (Earnings, Dividend, Tariffs, and Sector M&A)

Summary• PG closed Friday, November 7 at $146.98, sitting near the low end of its 52‑week range. Market cap is about $343B. StockAnalysis+1• P&G’s latest quarter delivered net sales of $22.4B, organic sales +2%, and core EPS of $1.99. FY26 guidance: all‑in sales +1% to +5%, core EPS $6.83–$7.09; management now bakes in ~$400M after‑tax tariff headwind and ~$100M commodity headwind, offset by an FX tailwind of ~$300M. PG Investor• Dividend watch: the next $1.0568 per‑share payout lands Monday, November 17. Trailing forward yield is ~2.9% at current prices. PG Investor+1• Leadership transition: COO Shailesh Jejurikar becomes CEO on Jan. 1, 2026; Jon Moeller shifts to executive chairman—operational continuity is expected but investors will listen for transition color. us.pg.com• Legal overhang to watch: a federal judge just allowed a lawsuit over Kid’s Crest packaging to proceed. While damages, if any, are unclear, headlines can sway sentiment in the near term. Reuters• Sector backdrop: Kimberly‑Clark’s bid to buy Kenvue for >$40B reshapes staples, with implications for categories where P&G competes. Reuters+1• Macro this week: October CPI hits Thursday, Nov. 13. Into Monday, the 10‑year Treasury last printed ~4.11% and DXY hovered near 99.6—levels that often influence defensives’ multiples. Bureau of Labor
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth (UNH) premarket: Dividend set, UBS talk at 8:45 a.m. ET, raised guidance — what to watch on November 10, 2025

OverviewUnitedHealth Group starts the new week in the spotlight with a live interview at the UBS Global Healthcare Conference before the bell on Monday, alongside a fresh quarterly dividend declaration and a late-October guidance raise. Investors will be parsing any color on 2026 medical-cost trends, Medicare Advantage star ratings and policy tailwinds, ongoing DOJ matters, and integration updates after August’s Amedisys close. Centers for Medicare & Medicaid Services+3SEC+3UnitedHealth Group+3
Record 2026 Tax Refund Surge Looms as New Tax Cuts Fuel a $50 Billion “Stimulus”

Walmart (WMT) Stock: What to Know Before the Bell on November 10, 2025

At a glance• Last trade Friday: $102.59; 52‑week range $79.81–$109.58; forward P/E ~39; dividend yield ~0.92%. Reuters+1• Next catalyst: Q3 FY26 earnings expected Thursday, Nov. 20, 2025. Street consensus points to ~$0.60 EPS and ~$175B revenue. Nasdaq+2Zacks+2• Macro in focus this week: U.S. CPI for October on Thu., Nov. 13 and October retail sales on Fri., Nov. 14. Both can sway retail sentiment and big‑box shares. Bureau of Labor Statistics+1• Holiday catalysts: Walmart’s Black Friday “Deals Events” kick off Nov. 14, alongside new AI‑powered shopping features rolling out in the app and stores. Walmart Corporate News and Information+1
Medical Properties Trust (MPW) Today: $150M Buyback, Fresh 10‑Q, and New Institutional Buying — Nov. 8, 2025

Medical Properties Trust (MPW) Today: $150M Buyback, Fresh 10‑Q, and New Institutional Buying — Nov. 8, 2025

Medical Properties Trust, Inc. remained in the news cycle today with a cluster of investor‑focused updates: a new institutional holder report, fresh analysis of its newly authorized share repurchase, and the posting of its latest quarterly filing. Below is a concise roundup of what changed today and why it matters for shareholders. MarketBeat+2
Qualys (QLYS) Today — Nov 8, 2025: Analyst Upgrade Follows Q3 Beat; Guidance Raised as Stock Hovers Near $150

Qualys (QLYS) Today — Nov 8, 2025: Analyst Upgrade Follows Q3 Beat; Guidance Raised as Stock Hovers Near $150

Qualys, Inc. is ending the week with fresh analyst attention after posting a stronger‑than‑expected third quarter and raising full‑year guidance earlier this week. As of today, one outlet reports an upgrade to Buy while another highlights lifted EPS forecasts, keeping the cybersecurity name on radar for Google News and Discover readers tracking post‑earnings momentum. The shares are trading around the $150 mark. MarketBeat+1
Qualys (QLYS) News Roundup for Nov. 7–8, 2025: Analyst Upgrade, EPS Estimate Lift, and Stock Holds Near $150 After Q3 Beat

Qualys (QLYS) News Roundup for Nov. 7–8, 2025: Analyst Upgrade, EPS Estimate Lift, and Stock Holds Near $150 After Q3 Beat

Dateline: November 8, 2025 — Cybersecurity vendor Qualys, Inc. stayed in the headlines heading into the weekend, with fresh analyst reactions following Tuesday’s earnings beat, a state pension fund disclosing a larger stake, and continued chatter around its agentic‑AI roadmap. Below is a concise, Google News–ready digest of everything new about Qualys published November 7–8, 2025.
8 November 2025
EOSE News Today (Nov 8, 2025): Analyst Downgrade Caps Volatile Week After Record Q3; Warrants Jump as New Orders Build

EOSE News Today (Nov 8, 2025): Analyst Downgrade Caps Volatile Week After Record Q3; Warrants Jump as New Orders Build

Eos Energy Enterprises, Inc. closed out a whipsaw week with fresh weekend headlines: an analyst downgrade, a small fund trimming its position, and continued attention on the company’s Q3 results and growing long‑duration storage pipeline. Below is a concise roundup of what’s new today, plus the key numbers and catalysts investors are watching from this week’s earnings, contracts, and financing updates.
8 November 2025
Conduent (CNDT) Q3 2025 Earnings: Revenue Misses at $767M as Adjusted EBITDA Margin Climbs to 5.2%; FY 2025 Margin Outlook 5.0%–5.5%, Shares Slide

Conduent (CNDT) Q3 2025 Earnings: Revenue Misses at $767M as Adjusted EBITDA Margin Climbs to 5.2%; FY 2025 Margin Outlook 5.0%–5.5%, Shares Slide

Conduent Incorporated reported third‑quarter 2025 revenue of $767 million and Adjusted EBITDA of $40 million with a 5.2% margin, reflecting continued cost discipline even as top‑line pressure persisted. Management reiterated a full‑year 2025 Adjusted EBITDA margin outlook of 5.0%–5.5% alongside Adjusted Revenue guidance of $3.05–$3.10 billion. The stock fell sharply following the release. GlobeNewswire+1
Petrobras (PBR) jumps on Q3 results, R$12.16bn dividend and faster capex — Today, 7 November 2025

Petrobras (PBR) jumps on Q3 results, R$12.16bn dividend and faster capex — Today, 7 November 2025

Petróleo Brasileiro S.A. shares are higher today after the company’s third‑quarter print, a fresh dividend announcement and upbeat commentary on its 2025 investment pace. By 19:25 UTC, U.S.-listed PBR ADRs traded around $12.71 and PBR.A near $11.92. Brazilian preferreds PETR4 were also firmer in São Paulo around midday, at R$31.90. InfoMoney
1 242 243 244 245 246 262

Stock Market Today

  • Virax Biolabs Signs Exclusive Supply Pact With Fosun Diagnostics for Southeast Asia
    July 9, 2026, 8:49 AM EDT. Virax Biolabs Group Limited (NASDAQ: VRAX) has landed an exclusive commercial supply deal with Fosun Diagnostics to cover six Southeast Asian countries: Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia. The agreement is for Virax's ImmuneSelect immune profiling products, separate from its diagnostic platform that's still in the works. Virax can now supply products right away through purchase orders, eyeing near-term revenue and a wider regional presence. Fosun Diagnostics, under Fosun Pharma, will use its network for distribution across the region. The agreement leaves room for more products, higher volume, and the chance of OEM or private-label deals down the line. Pricing is set up for scale. The deal moves Virax further into the ASEAN diagnostics market.
Go toTop